Kings Point Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Kings Point Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$130K	Hold	500	–	–	0.01%	242
2021 Q4	$110K	Hold	500	–	–	0.01%	286
2021 Q3	$91K	Hold	500	–	–	0.01%	289
2021 Q2	$101K	Hold	500	–	–	0.01%	273
2021 Q1	$107K	Hold	500	–	–	0.01%	258
2020 Q4	$118K	Sell	500 -5	-1%	-$1.15K	0.01%	224
2020 Q3	$137K	Buy	+505	New	+$139K	0.02%	205

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Kings Point Capital Management's VRTX Position: Q1 2022 in Review

Kings Point Capital Management held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2022 at 500 shares worth $130K. The position accounts for 0.01% of the portfolio, ranked #242.

Kings Point Capital Management first reported a position in VRTX in Q3 2020 and has held it in 7 quarters since. The position peaked at $137K in Q3 2020. 1,071 funds tracked by Wall St. Rank hold VRTX as of Q1 2022.

Kings Point Capital Management held 500 shares of Vertex Pharmaceuticals worth $130K as of Q1 2022.
Kings Point Capital Management left its Vertex Pharmaceuticals share count unchanged in Q1 2022.
Vertex Pharmaceuticals made up 0.01% of Kings Point Capital Management's portfolio in Q1 2022, its #242 holding.
Kings Point Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2020 and has held it in 7 quarters since.
Kings Point Capital Management's Vertex Pharmaceuticals position peaked at $137K in Q3 2020.
1,071 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2022.

Based on Kings Point Capital Management's 13F filing for Q1 2022, filed 13 May 2022.